Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study

Xiang J, Sun P, Liu Z, Zhang Q, Song L, Liu J

Drug Design, Development and Therapy 2025, 19:10871-10883

Published Date: 8 December 2025